Prostate related diseases rank second to cardiovascular diseases in the male population. Prostate cancer, with approximately 220,000 new cases reported every year, is the third leading cause of death among males in the US.

More than 1,500,000 males are undergoing Biopsy for detection of Prostate cancer in the US every year. The current procedure, performed in a “blind” way has a very high false negative rate and is dramatically increasing the cost of the diagnosis (60% are repeated Biopsy).

Most of the treatments are radical that are likely to cause severe complications while treating low risk patients. 

The medical community is looking for solutions that will “open the eyes” of the Urologist that is taking the Biopsy and enable him to tailor the treatment to the disease, similar to the revolution made by Lumpectomy in the treatment of Breast cancer

The US congress has recognized the importance of this revolution and decided to invest $650M in supporting the development of technologies for Smart Biopsy and Focal treatment

The prostate cancer market is estimated at $4B in US alone and is growing annually, driven by the worldwide phenomena of the aging population together with strong trend for solutions for better preservation of quality of life.

UC CARE's platform patented technology for Smart Biopsy and Focal treatment of Prostate Cancer  utilizes the urethra as a ‘natural landmark’, and facilitates high sensitivity diagnostic, guidance and therapeutic means into well defined focal prostate areas.; offering efficacy while substantially reducing side effects and complications. 

The lines of products consist of low cost capital equipment and disposables, ensuring very high gross margins.

Shaike Schatzberger, Founder, CEO and Chairman of the Board

Roni Zvuloni, Ph.D., Founder and CTO

Galit Natan Eliyaho , CFO and COO

Miki Cohen, MD, Active Urologist and Medical Director